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OBJECTIVE — To assess the association of 1-h plasma glucose (1hPG) and inﬂammation
with normal glucose tolerance (NGT) and pre-diabetes.
RESEARCH DESIGN AND METHODS — A cohort of 1,062 subjects was enrolled.
After oral glucose load (oral glucose tolerance test), we compared subjects with NGT and
pre-diabetesaboveandbelowthe1hPGcutpoint(155mg/dl).Fibrinogenandleukocytescount
(whitebloodcells[WBCs])forsubclinicalinﬂammation,lipidratios,insulinsensitivity(Matsuda
index) were determined.
RESULTS — Patients with NGT and pre-diabetes (1hPG 155 mg/dl) showed a signiﬁcant
increase of inﬂammatory markers and lipid ratios (for all, P  0.05). In age-, sex-, and BMI-
adjusted analysis, 1hPG was associated with a signiﬁcantly higher WBC count and ﬁbrinogen
(P0.05).Patientswithelevated1hPGshowedahighlysigniﬁcantlowerinsulinsensitivitythan
subjects 1hPG (P  0.01).
CONCLUSIONS — Elevated1hPGinsubjectswithNGTandpre-diabetesisassociatedwith
subclinical inﬂammation, high lipid ratios, and insulin resistance. Therefore, 1hPG 155 mg/dl
could be considered a new “marker” for cardiovascular risk.
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re-diabetes identiﬁes subjects with
impaired fasting glucose (IFG) and/or
impaired glucose tolerance (IGT) at
high risk for type 2 diabetes; moreover, it is
associated with insulin resistance, subclinical
inﬂammation, and cardiovascular diseases
(CVDs) (1–4). Recently, 1-h hyperglycemia
(1hPG) during an oral glucose tolerance test
(OGTT) with a cut point of 155 mg/dl has
been indicated as a further risk factor for type
2diabetes(5,6)andshowedearlycarotidath-
erosclerosis (7). The aim of this study is to
evaluate the metabolic characteristics and in-
ﬂammation markers in subjects with normal
glucose tolerance (NGT) and pre-diabetes
with or without 1hPG 155 mg/dl.
RESEARCH DESIGN AND
METHODS— We examined a con-
secutive series of 1,062 subjects with no
history of diabetes, CVD, with any malig-
nant disease, liver or chronic kidney fail-
ure or inﬂammatory diseases, and with
anydrugsinterferingwithglucoseorlipid
metabolism. All subjects gave their writ-
ten informed consent before study partic-
ipation.Anthropometricaldataandblood
pressure were measured. After overnight
fasting, a 75-g OGTT with blood samples
at 0, 30, 60, 90, and 120 min was per-
formed. Plasma glucose level, triglycer-
ides, total cholesterol HDL cholesterol,
and serum uric acid were automatically
measured (Beckman Instruments, Brea,
CA), as well as ﬁbrinogen and leukocytes
(white blood cell [WBC]) count as sub-
clinicalinﬂammationmarkers.Plasmain-
sulin was determined by a standard assay
(Roche Diagnostics, Mannheim, Ger-
many). Insulin sensitivity was evaluated
by the Matsuda index (8), calculated as
10,000 per square root of (fasting glucose
[mg/dl]  fasting insulin [U/ml]) 
(mean glucose  mean insulin during
OGTT). Lipid ratios as triglycerides to
HDL cholesterol 3.5 and total choles-
terol to HDL cholesterol 5 were consid-
ered as predictors of CVD risk (9).
According to American Diabetes As-
sociation criteria (10), we considered
NGTandpre-diabetescategories;patients
with diagnosis of type 2 diabetes were ex-
cluded. The cut point of 1hPG during
OGTT 155 mg/dl was applied, subdi-
vidingallpatientsintofourgroups,below
and above the 1hPG cutoff (NGT high,
NGT low, pre-diabetes high, and pre-
diabeteslow).Diagnosisofmetabolicsyn-
drome was performed according to
National Cholesterol Education Program
Adult Treatment Panel III criteria (11).
Statistical analysis was performed using
SPSS15.0software.WeusedANCOVAto
compare differences between selected
groups in means and the Bonferroni test
to assess differences between selected
groups. Adjustment for age and sex was
made in all analyses. Statistical signiﬁ-
cance was considered with P  0.05.
RESULTS— Of 1,062 patients stud-
ied, 507 (47.7%) had NGT and 555
(52.3%) were pre-diabetic. Among sub-
jects with NGT, 122 (24.0%) had 1hPG
155 mg/dl during OGTT, while 433
(78.0%) of pre-diabetic patients showed
elevated 1hPG. Glucose 30 and 120
weresigniﬁcantlyhigherinNGThighand
pre-diabetic high versus NGT low and
pre-diabetic low patients (P  0.05),
while glucose 30,6 0 , and 120 were
highly signiﬁcantly elevated in subjects
with 1hPG 155 mg/dl versus NGT low
and pre-diabetes low (P  0.01). NGT
high and pre-diabetic high patients
showed a signiﬁcant increase (P  0.05)
of ﬁbrinogen level and WBC count with
respect to NGT low and pre-diabetic low
subjects; all subjects with any history of
CVD were excluded from the analysis
(Table 1). NGT high and pre-diabetic
high subjects were older, female, and had
higher BMI in comparison to NGT low
andpre-diabeticlowpatients;therefore,a
logistic regression analysis adjusted for
age, sex, and BMI was applied. After ad-
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and WBC count remained signiﬁcantly
associated with sex (P  0.001), age (P 
0.001), BMI (P  0.05), and 1hPG (P 
0.001). Triglyceride–to–HDL cholesterol
ratio was signiﬁcantly increased in NGT
high versus NGT low subjects, in pre-
diabetic low versus NGT low individuals,
in pre-diabetic high versus NGT low sub-
jects, and between pre-diabetic high and
NGT high patients (for all, P  0.05).
Higher signiﬁcant levels of total choles-
terol–to–HDL cholesterol ratio were
found in NGT high versus NGT low sub-
jects, in pre-diabetic low versus NGT low
individuals, in pre-diabetic high versus
NGT high patients, and in NGT low and
NGT high subjects (for all, P  0.05).
Signiﬁcant increased concentrations of
uricacidwereobservedinNGThighthan
NGT low subjects (P  0.05), in pre-
diabetic high versus pre-diabetic low pa-
tients, and NGT low and NGT high
patients (for all, P  0.05). A highly sig-
niﬁcant lower insulin sensitivity was
found between pre-diabetic high versus
pre-diabetic low and between NGT high
versus NGT low subjects (P  0.01).
Overall metabolic syndrome prevalence
was 43.5%. Considering those subjects
with 1hPG 155 mg/dl, 100% fulﬁlled
metabolic syndrome criteria, but 31.0%
of patients without metabolic syndrome
diagnosis revealed 1hPG 155 mg/dl.
CONCLUSIONS — Pre-diabetes is
associated with a high risk for type 2 dia-
betes,subclinicalinﬂammation,earlyath-
erosclerosis, and CVD. Moreover, it was
shownthatsubjectswithNGTwith1hPG
155mg/dlhadaﬁvefoldtype2diabetes
risk than subjects with NGT with 1hPG
below the cutoff of 155 mg/dl (5). In this
study, NGT high subjects showed in-
creasedWBCcountandﬁbrinogenlevels,
signs of subclinical inﬂammation, as pa-
tients with pre-diabetes and a signiﬁcant
worsening of lipid proﬁle than NGT low
patients. The mechanism that links ele-
vated 1hPG to subclinical inﬂammation
is probably due to hyperglycemia that
acutely increases circulating cytokine
concentrations by oxidative mechanisms,
and this effect is more pronounced in pa-
tients with impaired glucose regulation
(3).
Subjects with 1hPG 155 mg/dl
showed signiﬁcantly lower insulin sensi-
tivity (Matsuda index). As previously ob-
served, metabolic syndrome is strongly
associated with decreased insulin sensi-
tivity (12); therefore, the link observed
between elevated 1hPG and insulin resis-
tance could be explained by the high
prevalence of metabolic syndrome in pa-
tients with elevated 1hPG.
Wedecidedtomeasureinﬂammation
levelsbyﬁbrinogenandWBCcountwith-
outconsideringthemeasureofC-reactive
protein. It is important to underline that
the measurement of C-reactive protein
(CRP) concentration requires a speciﬁc
high-sensitivity assay method that is not
available in all laboratories; moreover,
several data have shown that elevated lev-
els of CRP were associated to increased
CVD, but recently, analysis of genetic
polymorphisms in the CRP gene in Cau-
casian subjects showed that these poly-
morphisms were not associated with an
increased risk of ischemic vascular dis-
ease(13),increasingthedoubtsaboutthe
reliability of such a measurement in clin-
ical practice. A high WBC count is
associated with increased CVD-related
morbidity and mortality in several popu-
lations and clinical settings; it may turn
out to be a less expensive and more
readily available risk CVD marker than
other currently available risk factors
(14,15).
In conclusion, our data show the rel-
evance of 1hPG 155 mg/dl as an im-
portant cutoff related to subclinical in-
ﬂammation, lipid disorders, and insulin
resistance; therefore, this threshold could
be seriously taken into consideration to
identify subjects at high CVD risk.
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